Search Thermo Fisher Scientific
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
图: 1 / 1
Olaratumab Antibody (MA5-41920) in SDS-PAGE
SDS-PAGE analysis of the recombinant Human PDGFRA/PDGFR2/CD140a protein expressed in CHO cells using a Olaratumab biosimilar monoclonal antibody (Product # MA5-41920). R denotes the lane was run under reducing conditions. NR denotes the lane was run under non-reducing conditions.
产品信息
MA5-41920
产品规格
种属反应
Human
宿主/亚型
Human
/ IgG1, kappa
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
抗原
Human PDGFRA/PDGFR2/CD140a
偶联物
形式
Liquid
浓度
3.22 mg/mL
纯化类型
Protein A
保存液
PBS, pH 7.4
内含物
no preservative
保存条件
-20° C, Avoid Freeze/Thaw Cycles
运输条件
Ambient (domestic); Wet ice (international)
RRID
AB_2911063
产品详细信息
Endotoxin level < 0.01EU/µg by LAL method
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.
靶标信息
Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-alpha with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Studies show that the treatment of olaratumab in combination with doxorubicin resulted in significant reduction of cancer cell proliferation and tumor growth. Olaratumab was granted accelerated approval (as Lartruvo) as initial therapy to treat adults with certain types of soft tissue sarcoma (STS) in October, 2016.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
生物信息学
蛋白别名: 3G3; IMC-3G3; LY3012207
